ReversPAH

ReversPAH is a disease-modifying therapeutic candidate developed by Artin Immunology (ARTIN Bioscience) for the treatment of Pulmonary Arterial Hypertension (PAH) and Idiopathic Pulmonary Arterial Hypertension (IPAH). Unlike traditional PAH therapies that primarily act as vasodilators to manage symptoms, ReversPAH targets the underlying vascular remodeling by inducing apoptosis in pathologically proliferating, death-resistant endothelial cells and lumen-obliterating cells within the lung vasculature. By clearing these obstructive cells, the drug aims to reopen occluded pulmonary arteries, significantly reduce pulmonary artery pressure, and improve right heart function. ReversPAH has been granted Orphan Drug Designation by the FDA and is currently being evaluated in Phase 2 clinical trials.